{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T18:59:16Z","timestamp":1776279556816,"version":"3.50.1"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T00:00:00Z","timestamp":1573948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23 AI097234"],"award-info":[{"award-number":["K23 AI097234"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K24 HL093294"],"award-info":[{"award-number":["K24 HL093294"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA18029"],"award-info":[{"award-number":["CA18029"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 AI118690"],"award-info":[{"award-number":["T32 AI118690"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA15074"],"award-info":[{"award-number":["CA15074"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The influence of humoral immunity on the prevention of primary cytomegalovirus (CMV) infection after hematopoietic cell transplantation (HCT) is poorly understood.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>To determine whether neutralizing antibodies (nAbs) against CMV pentameric complex (PC)-mediated epithelial cell entry decrease CMV infection after HCT, samples were analyzed from a randomized controlled trial of CMV intravenous immunoglobulin (IVIG) prophylaxis. Weekly serum from 61 CMV donor-positive\/recipient-negative (D+\/R\u2212) HCT patients (33 control, 28 CMV IVIG) was tested using a PC-entry nAb assay and quantitative CMV polymerase chain reaction (PCR).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There was a trend toward higher weekly PC-entry nAb titers (P = .07) and decreased CMV infection by PCR at viral load cutoffs of \u22651000 and \u226510 000 IU\/mL in the CMV IVIG arm. High nAb titers were not significantly protective against CMV infection later after HCT in both study arms. Among CMV-infected patients, each log2 increase in nAb titer was associated with an average 0.2 log10 decrease in concurrent CMV viral load after infection (P = .001; adjusted for study arm).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study provides initial support that CMV IVIG prophylaxis moderately enhances PC-entry nAB activity in D+\/R\u2212 HCT recipients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiz596","type":"journal-article","created":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T04:23:25Z","timestamp":1573619005000},"page":"1470-1479","source":"Crossref","is-referenced-by-count":8,"title":["Cytomegalovirus Humoral Response Against Epithelial Cell Entry-Mediated Infection in the Primary Infection Setting After Hematopoietic Cell Transplantation"],"prefix":"10.1093","volume":"221","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1318-2902","authenticated-orcid":false,"given":"Danniel","family":"Zamora","sequence":"first","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington"},{"name":"Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth M","family":"Krantz","sequence":"first","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret L","family":"Green","sequence":"first","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington"},{"name":"Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurel","family":"Joncas-Schronce","sequence":"first","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Blazevic","sequence":"first","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley C","family":"Edmison","sequence":"first","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meei-Li","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, University of Washington, Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terry","family":"Stevens-Ayers","sequence":"first","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8212-3789","authenticated-orcid":false,"given":"Keith R","family":"Jerome","sequence":"first","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington"},{"name":"Department of Laboratory Medicine, University of Washington, Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam P","family":"Geballe","sequence":"first","affiliation":[{"name":"Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington"},{"name":"Departments of Medicine and Microbiology, University of Washington, Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Boeckh","sequence":"first","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington"},{"name":"Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,11,17]]},"reference":[{"key":"2020040710052661000_CIT0001","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1172\/JCI45449","article-title":"Cytomegalovirus: pathogen, paradigm, and puzzle","volume":"121","author":"Boeckh","year":"2011","journal-title":"J Clin Invest"},{"key":"2020040710052661000_CIT0002","doi-asserted-by":"crossref","first-page":"10330","DOI":"10.1128\/JVI.79.16.10330-10338.2005","article-title":"Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism","volume":"79","author":"Wang","year":"2005","journal-title":"J Virol"},{"key":"2020040710052661000_CIT0003","doi-asserted-by":"crossref","first-page":"18153","DOI":"10.1073\/pnas.0509201102","article-title":"Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism","volume":"102","author":"Wang","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2020040710052661000_CIT0004","doi-asserted-by":"crossref","first-page":"10023","DOI":"10.1128\/JVI.78.18.10023-10033.2004","article-title":"Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes","volume":"78","author":"Hahn","year":"2004","journal-title":"J Virol"},{"key":"2020040710052661000_CIT0005","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1128\/JVI.01910-07","article-title":"Characterization of the human cytomegalovirus gH\/gL\/UL128-131 complex that mediates entry into epithelial and endothelial cells","volume":"82","author":"Ryckman","year":"2008","journal-title":"J Virol"},{"key":"2020040710052661000_CIT0006","article-title":"Pathogen at the gates: human cytomegalovirus entry and cell tropism","volume":"10:704","author":"Nguyen","year":"2018","journal-title":"Viruses"},{"key":"2020040710052661000_CIT0007","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1182\/blood-2002-03-0993","article-title":"Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity","volume":"101","author":"Boeckh","year":"2003","journal-title":"Blood"},{"key":"2020040710052661000_CIT0008","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1365-2141.1993.tb04641.x","article-title":"Cytomegalovirus viraemia and specific T-helper cell responses as predictors of disease after allogeneic marrow transplantation","volume":"83","author":"Ljungman","year":"1993","journal-title":"Br J Haematol"},{"key":"2020040710052661000_CIT0009","doi-asserted-by":"crossref","first-page":"17965","DOI":"10.1073\/pnas.1415310111","article-title":"Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies","volume":"111","author":"Kabanova","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2020040710052661000_CIT0010","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1128\/JVI.01809-09","article-title":"Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH\/gL\/UL128-131A complex","volume":"84","author":"Macagno","year":"2010","journal-title":"J Virol"},{"key":"2020040710052661000_CIT0011","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1126\/science.aat0066","article-title":"Strain-specific antibody therapy prevents cytomegalovirus reactivation after transplantation","volume":"363","author":"Martins","year":"2019","journal-title":"Science"},{"key":"2020040710052661000_CIT0012","doi-asserted-by":"crossref","first-page":"362ra145","DOI":"10.1126\/scitranslmed.aaf9387","article-title":"A replication-defective human cytomegalovirus vaccine for prevention of congenital infection","volume":"8","author":"Wang","year":"2016","journal-title":"Sci Transl Med"},{"key":"2020040710052661000_CIT0013","article-title":"Neutralization of diverse human","volume":"91:e02033-16","author":"Ha","year":"2017","journal-title":"J Virol"},{"key":"2020040710052661000_CIT0014","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1128\/JVI.01669-12","article-title":"A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques","volume":"87","author":"Wussow","year":"2013","journal-title":"J Virol"},{"key":"2020040710052661000_CIT0015","doi-asserted-by":"crossref","first-page":"e0183377","DOI":"10.1371\/journal.pone.0183377","article-title":"Comparison of homologous and heterologous prime-boost vaccine approaches using modified vaccinia Ankara and soluble protein to induce neutralizing antibodies by the human cytomegalovirus pentamer complex in mice","volume":"12","author":"Chiuppesi","year":"2017","journal-title":"PLoS One"},{"key":"2020040710052661000_CIT0016","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1016\/j.vaccine.2014.05.004","article-title":"Human cytomegalovirus gH\/gL\/UL128\/UL130\/UL131A complex elicits potently neutralizing antibodies in mice","volume":"32","author":"Wen","year":"2014","journal-title":"Vaccine"},{"key":"2020040710052661000_CIT0017","article-title":"Phase","volume":"61:e01794-16","author":"Ishida","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020040710052661000_CIT0018","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1099\/vir.0.83523-0","article-title":"Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial\/epithelial cells, but not fibroblasts, early during primary infection","volume":"89","author":"Gerna","year":"2008","journal-title":"J Gen Virol"},{"key":"2020040710052661000_CIT0019","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1016\/j.vaccine.2008.07.092","article-title":"Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection","volume":"26","author":"Cui","year":"2008","journal-title":"Vaccine"},{"key":"2020040710052661000_CIT0020","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1099\/vir.0.000203","article-title":"Role of cytomegalovirus (CMV)-specific polyfunctional CD8+ T-cells and antibodies neutralizing virus epithelial infection in the control of CMV infection in an allogeneic stem-cell transplantation setting","volume":"96","author":"Gim\u00e9nez","year":"2015","journal-title":"J Gen Virol"},{"key":"2020040710052661000_CIT0021","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1369-5274(02)00334-X","article-title":"Human cytomegalovirus persistence and latency in endothelial cells and macrophages","volume":"5","author":"Jarvis","year":"2002","journal-title":"Curr Opin Microbiol"},{"key":"2020040710052661000_CIT0022","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0092-8674(01)80014-3","article-title":"Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors","volume":"91","author":"S\u00f6derberg-Naucl\u00e9r","year":"1997","journal-title":"Cell"},{"key":"2020040710052661000_CIT0023","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1128\/JVI.73.6.4806-4812.1999","article-title":"Quantitative analysis of latent human cytomegalovirus","volume":"73","author":"Slobedman","year":"1999","journal-title":"J Virol"},{"key":"2020040710052661000_CIT0024","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1073\/pnas.95.7.3937","article-title":"Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells","volume":"95","author":"Hahn","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2020040710052661000_CIT0025","doi-asserted-by":"crossref","first-page":"11879","DOI":"10.1073\/pnas.91.25.11879","article-title":"Human cytomegalovirus latent infection of granulocyte-macrophage progenitors","volume":"91","author":"Kondo","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2020040710052661000_CIT0026","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/clinids\/19.2.287","article-title":"Strategies for the prevention of cytomegalovirus disease after marrow transplantation","volume":"19","author":"Goodrich","year":"1994","journal-title":"Clin Infect Dis"},{"key":"2020040710052661000_CIT0027","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/infdis\/164.3.483","article-title":"Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant","volume":"164","author":"Bowden","year":"1991","journal-title":"J Infect Dis"},{"key":"2020040710052661000_CIT0028","volume-title":"R: A Language and Environment for Statistical Computing [computer program]","author":"R Core Team","year":"2019"},{"key":"2020040710052661000_CIT0029","doi-asserted-by":"crossref","first-page":"e0146021","DOI":"10.1371\/journal.pone.0146021","article-title":"Dose-response analysis using R","volume":"10","author":"Ritz","year":"2015","journal-title":"PLoS One"},{"key":"2020040710052661000_CIT0030","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/infdis\/jiz181","article-title":"Prospective assessment of cytomegalovirus immunity in high-risk donor-seropositive\/recipient-seronegative liver transplant recipients receiving either preemptive therapy or antiviral prophylaxis","volume":"220","author":"Limaye","year":"2019","journal-title":"J Infect Dis"},{"key":"2020040710052661000_CIT0031","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1128\/JCM.42.3.1142-1148.2004","article-title":"Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR","volume":"42","author":"Boeckh","year":"2004","journal-title":"J Clin Microbiol"},{"key":"2020040710052661000_CIT0032","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1128\/JCM.03292-15","article-title":"Commutability of cytomegalovirus WHO International Standard in Different Matrices","volume":"54","author":"Jones","year":"2016","journal-title":"J Clin Microbiol"},{"key":"2020040710052661000_CIT0033","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2020040710052661000_CIT0034","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00430-018-0558-x","article-title":"Role of pentamer complex-specific and IgG subclass 3 antibodies in HCMV hyperimmunoglobulin and standard intravenous IgG preparations","volume":"208","author":"Schampera","year":"2019","journal-title":"Med Microbiol Immunol"},{"key":"2020040710052661000_CIT0035","doi-asserted-by":"crossref","first-page":"11","DOI":"10.7326\/0003-4819-97-1-11","article-title":"Cytomegalovirus immune plasma in bone marrow transplant recipients","volume":"97","author":"Winston","year":"1982","journal-title":"Ann Intern Med"},{"key":"2020040710052661000_CIT0036","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/0002-9343(84)90332-2","article-title":"Prevention of cytomegalovirus infection by prophylaxis with an intravenous, hyperimmune, native, unmodified cytomegalovirus globulin. Randomized trial in bone marrow transplant recipients","volume":"76","author":"Condie","year":"1984","journal-title":"Am J Med"},{"key":"2020040710052661000_CIT0037","first-page":"132","article-title":"A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT)","volume":"83","author":"Zikos","year":"1998","journal-title":"Haematologica"},{"key":"2020040710052661000_CIT0038","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1042\/bj2410313","article-title":"Molecular biology and immunology of cytomegalovirus","volume":"241","author":"Griffiths","year":"1987","journal-title":"Biochem J"},{"key":"2020040710052661000_CIT0039","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1146\/annurev-immunol-032712-100001","article-title":"Control of human viral infections by natural killer cells","volume":"31","author":"Jost","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"2020040710052661000_CIT0040","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/infdis\/jiw315","article-title":"Association of human immunoglobulin G1 heavy chain variants with neutralization capacity and antibody-dependent cellular cytotoxicity against human cytomegalovirus","volume":"214","author":"Vietzen","year":"2016","journal-title":"J Infect Dis"},{"key":"2020040710052661000_CIT0041","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1086\/654931","article-title":"Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients","volume":"202","author":"Abate","year":"2010","journal-title":"J Infect Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiz596\/30927427\/jiz596.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/221\/9\/1470\/33020168\/jiz596.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/221\/9\/1470\/33020168\/jiz596.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T14:05:58Z","timestamp":1586268358000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/221\/9\/1470\/5627782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,17]]},"references-count":41,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,11,17]]},"published-print":{"date-parts":[[2020,4,7]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiz596","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,5,1]]},"published":{"date-parts":[[2019,11,17]]}}}